title: An assessment of ONRAB oral rabies vaccine persistence in free-ranging mammal populations in Ontario, Canada.
abstract: ONRAB is a rabies glycoprotein recombinant human adenovirus type 5 oral vaccine developed for application in baits to control rabies in wildlife populations. Prior to widespread use of ONRAB, both the safety and effectiveness of this vaccine required investigation. While previous research has focused on field performance and the persistence and pathogenicity of ONRAB in captive animals, we sought to examine persistence and shedding of ONRAB in populations of free-ranging target and non-target mammals. We collected oral and rectal swab samples from 84 red foxes, 169 striped skunks, and 116 raccoons during 2007 and 2008 in areas where ONRAB vaccine baits were distributed. We also analyzed 930 tissue samples, 135 oral swab and 138 rectal swab samples from 155 non-target small mammals from 10 species captured during 2008 at sites treated with high densities of ONRAB vaccine baits. Samples were screened for the presence and quantity of ONRAB DNA using quantitative real-time PCR. None of the samples that we analyzed from target and non-target species contained quantities of ONRAB greater than 10(3)EU/mL of ONRAB DNA which is a limit that has previously been applied to assess viral shedding. This study builds on similar research and suggests that replication of ONRAB in animals is short-lived and the likelihood of horizontal transmission to other organisms is low.
authors.affiliation: Wildlife Research and Development Section, Ontario Ministry of Natural Resources, 2140 East Bank Drive, DNA Building, Trent University, Peterborough, Ontario, K9J 7B8, Canada.
authors.forename: K G
authors.initials: KG
authors.lastname: Sobey
authors.forename: A A
authors.initials: AA
authors.lastname: Walpole
authors.forename: R
authors.initials: R
authors.lastname: Rosatte
authors.forename: C
authors.initials: C
authors.lastname: Fehlner-Gardiner
authors.forename: D
authors.initials: D
authors.lastname: Donovan
authors.forename: P
authors.initials: P
authors.lastname: Bachmann
authors.forename: S
authors.initials: S
authors.lastname: Coulson
authors.forename: A
authors.initials: A
authors.lastname: Beresford
authors.forename: L
authors.initials: L
authors.lastname: Bruce
authors.forename: C J
authors.initials: CJ
authors.lastname: Kyle
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D006801:Humans; D008322:Mammals / Q000276:immunology*; D009864:Ontario; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D060888:Real-Time Polymerase Chain Reaction; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D011819:Rabies Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; C079096:adenovirus 5, rabies glycoprotein recombinant vaccine